We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

OBT Licenses BioWa’s POTELLIGENT® Technology for the Research and Development of its Therapeutic Antibodies in Cancer

News   Apr 07, 2011

 
OBT Licenses BioWa’s POTELLIGENT® Technology for the Research and Development of its Therapeutic Antibodies in Cancer
 
 
Advertisement
 

RELATED ARTICLES

Fungal Compound Inhibits BMP Receptors

News

Researchers in the group of Jeroen den Hertog, in collaboration with researchers in Leiden, have found that a compound inhibits a group of proteins called BMP receptors. This compound, called cercosporamide, was previously only known to inhibit a different group of proteins.

READ MORE

Phase 3 Trial Assesses Dual-Antibody Injection's Ability To Prevent SARS-CoV-2 Infection

News

A Phase III, randomized, double-blinded, placebo-controlled trial will help to determine if the dual-antibody treatment, REGN-COV2, can prevent infection in individuals who share a home with someone who has been diagnosed with COVID-19.

READ MORE

Redesigning Existing Antibiotics To Outmanoeuver Resistant Bacteria

News

Researchers at UC San Francisco are tackling antibiotic resistance using a different approach: redesigning existing antibiotic molecules to evade a bacterium’s resistance mechanisms.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE